Future Prospects of Novel Carrier-Based Pharmacotherapy

Psoriasis is a serious dermal plight characterised by inflammation and hyper-proliferation of the keratinized cells of the epidermis. Because of the complicated disposition of the disease, it has a severe pessimistic impact on the patient's overall well-being. Currently, a variety of medications are available for treating psoriasis, including conventional topical therapies, UVB therapy, intrinsic or systemic immune-modulators, and biologics, which aim to alleviate symptoms and thereby improve the quality of life for patients. Conventional topical therapies, though they constitute first-line therapy, have restricted efficacy because of the mediocre drug penetration properties, deposition, and dose-related toxicity. The latest progression in topical treatments, specifically with micro-scaled medical devices like micro-needles and nanoparticle-based carriers, lipid nanoparticles offer a promising future with significantly better therapeutic potency as it has a way better skin permeation, controlled release of the drug, targeting specific pathways, such as IL-23 inhibitors like mirikizumab and RORγt inhibitors, hence contributing to better drug delivery and efficacy for psoriatic plaques. These innovative and efficient therapies may cut down the side effects and may lead to improved and better patient adherence.